The Genetics Podcast EP 198: Reimagining clotting disorders: Patient voices and “unreasonable” leadership with Benny Sorenson of Hemab Therapeutics
14 snips
Jul 31, 2025 
Benny Sorensen, CEO of Hemab Therapeutics, leads a groundbreaking company focused on innovative blood clotting therapies, prioritizing patient voices. He shares how persistence and an 'unreasonable' approach catalyzed their first drug development program. The discussion highlights advancements in treating conditions like Glanzmann's thrombocytopenia, the importance of gender considerations in healthcare, and lessons learned from integrating patient experiences. Benny reflects on the balance between leadership and fatherhood, inspiring a vision for empathetic, effective therapies.
AI Snips
Chapters
Transcript
Episode notes
Hemophilia vs Neglected Bleeding Disorders
- Hemophilia care evolved through decades of biotech revolutions to modern therapies.
- Many other bleeding disorders await similar innovation, often relying on outdated acute bleed management.
Gender Equality in Bleeding Disorders
- Autosomal bleeding disorders affect men and women equally, unlike X-linked hemophilia.
- Women with these disorders bleed differently but need equal attention and treatment.
Flexible Therapy and Collaboration
- Choose therapeutic modalities based on patient needs rather than one technology.
- Collaborate broadly to leverage expertise beyond your core team for faster, higher-quality drug development.